42PLUS1 Successfully Launched Its First Edition of Europe’s Largest Prized Pitch Award With 100 Applications From Over 17 Countries Held at the DxPx Conference U.S.

DUSSELDORF, Germany- With their submission to the 42PLUS1 Pitch Award numerous participants have already taken the first step to winning 2,000,000 USD funding for the most innovative business ideas. The winners of the 42PLUS1 Pitch Award will be elected from a renowned jury of industry experts and investors at the grand finale at the DxPx Conference EU, November 16th in Dusseldorf, Germany. The DxPx Conference is an established Industry & Investor Partnering Conference for executives of the Diagnostics, Digital Health, Precision Medicine and Life Science Tools industry.

“We are pleased about the large number of pitch submissions, which suggests that there are many innovative startups with a pipeline of ideas and break-through technologies out there. Our mission is to support young companies as well as to promote novel solutions in Diagnostics, Digital Health, Precision Medicine and Life Science Tools”, says Lena Ehrenpreis, initiator of the DxPx Conference and the 42PLUS1 Pitch Award.

8 satellite finalists pitched live at the DxPx Conference US on July 27th and the jury chose one winner, getting a Wildcard for the finale at DxPx Conference EU: Alertgy, presented by CEO Marc Rippen. Alertgy developed a 100% non-invasive, real-time, real blood glucometer that lasts a long time. As a cutting-edge biotech company, they’re working to revolutionize the way diabetics and pre-diabetics manage their disease. The organizer SLS Partnering is inviting Marc to the DxPx Conference EU, November 16th, to pitch with 7 other finalists for 1,500,000 USD funding. The other seven finalists still need to be found. So, entrepreneurs can submit their pitches online on www.42plus1.com starting September 6th.

Pitches were not the only interesting agenda point at the first DxPx Conference US (July 27th – 31st), connecting leaders of the industries as well as renowned investors and startup founders with a locally driven approach and a focus on the US. Even as an all-digital format, due to the pandemic, the organizers successfully achieved almost 500 streams, 800 meetings, 200 participants from 13 countries with a strong American focus – 50% from the US and Canada. With renowned Knowledge Partners like Brown Gibbons Lang & Company, McDermott Will & Emery and Hologic and a versatile conference program followed by 4 days of digital partnering, it became a key date for the professionals. The conferences panels addressed burning topics such as IPOs and SPACs, precision medicine as the future of novel cancer treatment, regulatory and reimbursement hurdles for digital diagnostic companies in the US, and the use of AI in medical diagnostics with side notes from great speakers like Uplaksh Kumar (GRAIL), Alissa Lynch (Google) and Debbie Lin (Boehringer Ingelheim).

SLS Partnering is now looking forward to its flagship – the DxPx Conference EU, parallel to MEDICA on November 16th at the Maritim Hotel in Dusseldorf, Germany. To ensure maximum flexibility and outcome the participants will be able to use the digital partnering platform for 8 full days from November 12th – 20th.

About 42PLUS1®:

With a prize funding of 2,000,000 USD, 42PLUS1 is the highest-prized industry dedicated Pitch Award in Europe and one of the biggest worldwide dedicated to the DxPx Galaxy of Diagnostics, Digital Health, Precision Medicine and Life Science Tools. It underlines SLS Partnering’s commitment to support startups and growth companies and can now make an even bigger difference for the DxPx startup galaxy.

About DxPx®:

DxPx was first hosted in 2019 as an international Industry & Investor Partnering Conference for executives from the Diagnostics, Digital Health, Precision Medicine & Life Science Tools industry to explore financing, licensing and M&A opportunities. The annual flagship conference takes place each November in Dusseldorf, Germany and is accompanied with satellite conferences in the US and China throughout the year.

About SLS Partnering:

SLS Partnering is an event & marketing agency that tailors its services to the specific needs of the Life Science industry. Built by scientists and marketeers, SLS Partnering is your trusted partner to translate technology and scientific content into high-quality marketable stories that trigger interest and emotion with customers and investors.

Press Contact

Jacqueline Soldan

SLS Partnering GmbH

Oliver Dick

Oliver brings 30+ years of experience in the life sciences industry, has worked in pharma, biotechnology and in vitro diagnostics. His areas of expertise fall under Supply Chain Management, Planning, Production, QC, QA, Engineering, Technology Transfer and Process Improvement. Amongst his vast experience, Oliver held functions such as Vice President of Global Manufacturing at QIAGEN, Chief Operating Officer at Miltenyi Biotec or Chief Operating Office of Resolve Biosciences. He demonstrated exceptional leadership and expertise in driving manufacturing excellence on a global scale.

Oliver has a proven ability to streamline processes, optimize production efficiency, and foster a culture of innovation. He was responsible for strategy development, scaling, cost control and quality and was part of multiple M&A projects and transfer of many new products from acquisition or own development. Today Oliver offers his expertise mainly through his own Consultancy Service Company ODICON.


Christoph Brandenberger is a Managing Director at BGL and a leader in the firm’s Diagnostics, Research Tools & Medical Devices investment banking group. He has more than 20 years of experience in all aspects of mergers and acquisitions, commercialization and partnering agreements, and private placements.

A native of Austria and fluent in German, Christoph’s investment banking experience, coupled with his background in international business, has made him a sought-after advisor in both the domestic and international healthcare markets.

Prior to joining BGL, Christoph served as managing director for Healthios Capital Markets, LLC. Christoph started his career as a financial analyst for Bank of America Securities.


John Riddle

John Riddle is a Managing Director and member of the BGL Executive Committee. He has more than 30 years of investment banking and capital markets experience, advising clients across a broad spectrum of mergers and acquisitions, capital markets activities, and strategic assignments.

John leads BGL’s advisory activities in the Healthcare & Life Sciences investment banking group, which comprises both corporate investment banking and real estate capital markets capabilities. Together with his team, John maintains an ongoing coverage effort with broad activity across several sectors, including health facilities, physician services, and ancillary providers; diagnostics and research tools; medical device and products; and select healthcare technology verticals, including payor services, data analytics, and clinical automation.


Dr. Mirko Stange

Born in Bremen, Germany in 1974, Dr. Mirko Stange is a diagnostics and life sciences expert with a proven track record in turning around and commercializing innovations. He possesses extensive executive management experience, having led diagnostics and biotech startups, as well as developing and conducting consulting products. Following the completion of his Ph.D. in Biochemistry and Biophysics at the University of North Carolina at Chapel Hill, Dr. Stange began his career in 2004 at the strategy consultancy McKinsey. Subsequently, he worked with the turnaround-specialized advisory firm Droege & Comp., primarily serving clients from the pharma and chemistry industry in Germany and Switzerland.

In 2008, he founded an independent Life Sciences consultancy in Germany where, to date, he leads and directs a team of international experts. This team identifies and funds SMEs with high potential for national and international leverage. In addition to his over ten years of experience in independent corporate finance and management consulting, Mirko Stange provides interim management services to selected clients. To date, three companies co-founded and managed/advised by Dr. Stange have been successfully exited. Leveraging his scientific background, he is also a named inventor on several granted and pending patents.


FName LName

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.